𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combination chemotherapy including Adriamycin for advanced transitional cell carcinoma of the urinary tract

✍ Scribed by Toshihiko Kotake; Michiyuki Usami; Tsuneharu Miki; Masao Kuroda; Koji Obata; Masao Osafune; Hideki Fujioka; Yutaka Takasugi


Publisher
Springer
Year
1983
Tongue
English
Weight
493 KB
Volume
11
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


A study of cyclophosphamide, adriamycin,
✍ Dennis L. Citrin; Tom F. Hogan; Tom E. Davis πŸ“‚ Article πŸ“… 1983 πŸ› John Wiley and Sons 🌐 English βš– 424 KB πŸ‘ 2 views

Twenty patients with locally advanced and/or metastatic transitional cell cancer of the urinary tract were treated with cyclophosphamide 500 mg/m2, Adriamycin (doxorubicin) 40 mg/m2 and cis-platinum (CDDP) 40 mg/m2 given every three weeks for 2 cycles, alternating with methotrexate 40 mg/m2 weekly f

Chemotherapy of advanced transitional ce
✍ Frank M. Torti; W. Graydon Harker πŸ“‚ Article πŸ“… 1983 πŸ› Springer 🌐 English βš– 390 KB

Activity has been demonstrated for both single agents and combination chemotherapy in advanced transitional cell carcinoma of the uroepithelium. Regimens are palliative; duration of response has been modest, usually ranging from 3 to 8 months. There are few complete responders; occasional patients r

Gemcitabine and carboplatin in advanced
✍ Miquel NoguΓ©-Aliguer; Joan Carles; Antonio Arrivi; Oscar Juan; Lorenzo Alonso; A πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 89 KB

## Abstract ## BACKGROUND Cisplatin‐based combinations are considered to be the standard treatment for advanced transitional cell carcinoma (TCC) of the urothelium. Many of the patients are elderly with concomitant diseases or impaired renal function. We studied the tolerance and activity of the g